OMX Nordic 40
|
2 356,17
|
-2,55
|
-0,11 %
|
Analysen zu OMX Nordic 40-Werten
| 04.12.24 | ABB Underweight | Barclays Capital | |
| 03.12.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.12.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 02.12.24 | Hennes & Mauritz AB Buy | UBS AG | |
| 02.12.24 | Novo Nordisk Neutral | UBS AG | |
| 01.12.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 28.11.24 | Hennes & Mauritz AB Underweight | JP Morgan Chase & Co. | |
| 27.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 27.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 27.11.24 | Volvo AB Overweight | JP Morgan Chase & Co. | |
| 26.11.24 | ABB Sector Perform | RBC Capital Markets | |
| 26.11.24 | Volvo AB Sector Perform | RBC Capital Markets | |
| 26.11.24 | Hennes & Mauritz AB Sector Perform | RBC Capital Markets | |
| 25.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 25.11.24 | Hennes & Mauritz AB Buy | Deutsche Bank AG | |
| 20.11.24 | Volvo AB Buy | Jefferies & Company Inc. | |
| 20.11.24 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 20.11.24 | AstraZeneca Neutral | UBS AG | |
| 19.11.24 | Hennes & Mauritz AB Sell | Goldman Sachs Group Inc. | |
| 19.11.24 | Volvo AB Neutral | UBS AG | |
| 18.11.24 | Novo Nordisk Neutral | UBS AG | |
| 15.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 14.11.24 | Volvo AB Neutral | JP Morgan Chase & Co. | |
| 14.11.24 | A.P. Moeller - Maersk A-S Neutral | Goldman Sachs Group Inc. | |
| 13.11.24 | AstraZeneca Halten | DZ BANK | |
| 13.11.24 | AstraZeneca Hold | Deutsche Bank AG | |
| 13.11.24 | Novo Nordisk Neutral | UBS AG | |
| 13.11.24 | Hennes & Mauritz AB Buy | UBS AG | |
| 13.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 12.11.24 | AstraZeneca Hold | Jefferies & Company Inc. | |
| 12.11.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 12.11.24 | AstraZeneca Sell | UBS AG | |
| 12.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 12.11.24 | ABB Neutral | JP Morgan Chase & Co. | |
| 11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 11.11.24 | Novo Nordisk Neutral | UBS AG | |
| 11.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 08.11.24 | Novo Nordisk Overweight | Barclays Capital |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.